Skip to main content

Table 1 Patient and treatment characteristics

From: Risk factors for pneumonitis in advanced extrapulmonary cancer patients treated with immune checkpoint inhibitors

Patient characteristics

All patients

n = 110

No pneumonitis patients

n = 91

Pneumonitis patients

n = 19

p-value

No pneumonitis vs pneumonitis (≥ grade 1)

Age

   

0.44

  Median (range)

68 (34–84)

67 (34–84)

69 (53–81)

 

Sex

   

0.14

  Male

82

65

17

 

  Female

28

26

2

 

Smoking history

   

0.10

  Current

25

19

6

 

  Former

45

35

10

 

  Never

40

37

3

 

Amount of smoking (pack-years)

   

0.024

  Median (range)

21.75 (0–190)

15.00 (0–98)

36.75 (0–190)

 

Types of cancer

   

0.40

  Head and neck cancer

23

17

6

 

  Gastric cancer

17

14

3

 

  Renal cell cancer

29

23

6

 

  Urothelial cancer

15

12

3

 

  Malignant melanoma

25

24

1

 

  Peritoneal mesothelioma

1

1

0

 

BMI (kg/m2)

   

0.67

  Median (range)

20.37 (14.61–36.49)

20.56 (14.63–36.49)

20.08 (14.61–32.36)

 

Immunotherapy

   

0.41

  NIVO

95

79

16

 

  PEM

15

12

3

 

ILD

   

0.068

  Yes

10

6

4

 

  No

100

85

15

 

Lung metastasis

   

0.31

  Yes

69

55

14

 

  No

41

36

5

 

Treatment line

   

0.66

  Median (range)

2 (1–7)

2 (1–7)

3 (1–5)

 

TKI

   

1.00

  Yes

28

23

5

 

  No

82

68

14

 

CRP (mg/dl)

   

0.82

  Median (range)

0.98 (0.01–11.97)

0.98 (0.01–11.97)

0.79 (0.08–10.49)

 

NLR

   

0.33

  Median (range)

3.84 (0.77–39.78)

3.79 (1.00–39.78)

4.46 (0.77–11.36)

 

Patient characteristics

Asymptomatic (Grade 1) pneumonitis patients

n = 7

Symptomatic (≥ grade 2) pneumonitis patients

n = 12

p-value

Asymtomatic (≤ grade 1) vs Symptomatic (≥ grade 2)

Age

  

0.72

  Median (range)

73 (58–81)

68.5 (53–74)

 

Sex

  

0.28

  Male

6

11

 

  Female

1

1

 

Smoking history

  

0.31

  Current

2

4

 

  Former

4

6

 

  Never

1

2

 

Amount of smoking (pack-years)

  

0.057

  Median (range)

36.00 (0–67.5)

40.88 (0–190)

 

Types of cancer

  

0.090

  Head and neck cancer

4

1

 

  Gastric cancer

2

2

 

  Renal cell cancer

0

6

 

  Urothelial cancer

0

3

 

  Malignant melanoma

1

0

 

  Peritoneal mesothelioma

0

0

 

BMI (kg/m2)

  

0.69

  Median (range)

20.16 (17.63–25.68)

20.04 (14.61–32.36)

 

Immunotherapy

  

0.21

  NIVO

7

9

 

  PEM

0

3

 

ILD

  

0.077

  Yes

1

3

 

  No

6

9

 

Lung metastasis

  

0.029

  Yes

3

11

 

  No

4

1

 

Treatment line

  

0.073

  Median (range)

2 (1–3)

2 (3–5)

 

TKI

  

0.18

  Yes

0

5

 

  No

7

7

 

CRP (mg/dl)

  

0.71

  Median (range)

0.47 (0.25–10.49)

1.16 (0.08–9.7)

 

NLR

  

0.35

  Median (range)

3.69 (0.77–11.36)

4.80 (2.35–10.42)

 
  1. BMI Body mass index, NIVO Nivolumab, PEM Pembrolizumab, ILD Interstitial lung disease, LM Lung metastasis, TKI Tyrosine kinase inhibitor, NLR Neutrophil-to-lymphocyte ratio